Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-01-23
2003-05-06
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S456000, C514S822000, C514S824000, C514S834000, C435S007210, C424S085200, C424S183100
Reexamination Certificate
active
06559133
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention is directed to the use of flavone 8-acetic acid and its homologues in vascular and cardiovascular intervention and in acute coronary syndromes, alone or in combination with thrombolytic agents, antithrombotic agents, anticoagulants, or antiplatelet agents.
Vascular and cardiovascular diseases, including stroke, myocardial infarction, and blood clots, continue to be major causes of morbidity and mortality in the United States and other advanced industrial countries. A number of genetic and environmental factors have been linked to the occurrence of vascular and cardiovascular diseases, including genetic errors of lipid or lipoprotein metabolism and lifestyle factors such as tobacco smoking, the consumption of foods high in saturated fat, and lack of exercise. Despite a number of recent advances in the diagnosis and treatment of such diseases, they are still among the leading causes of death in the United States.
Therefore, there is a need for improved treatments for vascular and cardiovascular diseases. There is a particular need for agents and treatments that can treat both thrombosis and vasoconstriction in a coordinated manner.
SUMMARY
The administration of a flavone 8-carboxylic acid is effective in treating vascular and cardiovascular conditions and acute coronary syndromes.
In particular, one aspect of a method according to the present invention comprises a method for treating a vascular or cardiovascular condition or acute coronary syndromes comprising administering an effective amount of a flavone 8-carboxylic acid of formula (I)
where n is an integer from 1 to 3 to a mammal suffering from a vascular or cardiovascular condition or acute coronary syndromes.
Preferably, the flavone 8-carboxylic acid is flavone 8-acetic acid, in which n is 1.
The mammal can be a human or a socially or economically important nonhuman animal.
The flavone 8-carboxylic acid can act by reducing thrombosis or by reducing vasoconstriction.
Another aspect of the present invention is a method for treating a vascular or cardiovascular condition or acute coronary syndromes comprising administering an effective amount of a flavone 8-carboxylic acid of formula (I) where n is an integer from 1 to 3 and an additional agent that can ameliorate a vascular or a cardiovascular condition or acute coronary syndromes to a mammal suffering from a vascular or cardiovascular condition or acute coronary syndromes.
The additional agent can be selected from the group consisting of a thrombolytic agent, an antithrombotic agent, an anticoagulant, or an antiplatelet agent.
Thrombolytic agents include streptokinase, tissue plasminogen activator (tPA), and urokinase and modifications or derivatives of these molecules. Aminocaproic acid is an antithrombotic agent. Anticoagulants include heparin, warfarin, dicoumarol, phenprocoumon, acenocoumarol, ethyl biscoumacetate, and anisindione. Antiplatelet agents include aspirin, dipyramidole, ticlopidine, and plavix.
Yet another aspect of the present invention is a pharmaceutical composition comprising:
(1) an effective amount of a flavone 8-carboxylic acid of formula (I) where n is an integer from 1 to 3; and
(2) a pharmaceutically acceptable carrier, the pharmaceutical composition being formulated for the treatment of a vascular or cardiovascular condition or acute coronary syndromes.
REFERENCES:
patent: 2897211 (1959-07-01), P. da Re
patent: 2921070 (1960-01-01), P. da Re
patent: 3812156 (1974-05-01), Bonola et al.
patent: 4057641 (1977-11-01), Appleton et al.
patent: 4122200 (1978-10-01), Briet et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4783533 (1988-11-01), Briet et al.
patent: 4791136 (1988-12-01), Batchelor et al.
patent: 4904690 (1990-02-01), Aono et al.
patent: 5061488 (1991-10-01), Wiltrout et al.
patent: 5096707 (1992-03-01), Wiltrout et al.
patent: 5118684 (1992-06-01), Attwood et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5227368 (1993-07-01), Gerlach et al.
patent: 5238954 (1993-08-01), Aristoff
patent: 5585243 (1996-12-01), Aster et al.
patent: 5756538 (1998-05-01), Cassels et al.
patent: 59076079 (1984-04-01), None
patent: 59076080 (1984-04-01), None
patent: 59222486 (1984-12-01), None
patent: WO 2001052839 (2001-07-01), None
Mruk et al., “Antithrombotic efficacy of low-molecular weight heparin in deep arterial injury.” Arterioscler. Thromb. 12(2), pp. 250 255, 1992.
D.R. Phillips et al., “The Platelet Membrane Glycoprotein IIb-IIIa Complex,”Blood71:831-843 (1988).
M.H. Kroll & A.I. Schafer, “Biochemical Mechanisms of Platelet Activation,”Blood74: 1181-1195 (1989).
P.S. Frenette & D.D. Wagner, “Molecular Medicine: Adhesion Molecules—Part I,”New Eng. J. Med..334: 1526-1529 (1996).
P.S. Frenette & D.D. Wagner, “Adhesion Molecules—Part II: Blood Vessels and Blood Cells,”New Eng. J. Med.335: 43-45 (1996).
J. Lefkovits & E.J. Topol, “The Clinical Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Ischemic Heart Disease,”Cleve. Clin. J. Med.63: 181-189 (1996).
R.C. Becker, “Antiplatelet Therapy,”Science&Medicine3: 12-21 (1996).
Z.M. Ruggeri, “Mechanisms Initiating Platelet Thrombus Formation,”Thrombosis&Hemostatis78: 611-616 (1997).
D.J. Kerr & S.B. Kaye, “Flavone Acetic Acid—Preclinical and Clinical Activity,”Eur. J. Cancer Clin. Oncol.25: 1271-1272 (1989).
J. Rubin et al., “Flavone-8-Acetic Acid Inhibits Ristocetin-Induced Platelet Agglutination and Prolongs Bleeding Time,”Lancet2: 1081-1082 (1987).
G.P. Smith et al., “Flavone Acetic Acid (NSC 347512) Induces Hemorrhagic Necrosis of Mouse Colon 26 and 38 Tumors,”Eur. J. Cancer Clin. Oncol.23: 1209-1211 (1987).
S. Hill et al., “Vascular Collapse After Flavone Acetic Acid: A Possible Mechanism of Its Anti-Tumor Action,”Eur. J. Cancer Clin. Oncol.25: 1419-1424 (1989).
J.C. Murray et al., “Flavone Acetic Acid Induces a Coagulopathy in Mice,”Br. J. Cancer60: 729-733 (1989).
G. Thurston et al., “Anticoagulant Treatment Does Not Affect the Action of Flavone Acetic Acid in Tumor-Bearing Mice,”Br. J. Cancer64: 689-692 (1991).
J.C. Murray et al., “Selective Induction of Endothelial Cell Tissue Factor in the Presence of a Tumor-Derived Mediator: A Potential Mechanism of Flavone Acetic Acid Action in Tumor Vasculature,”Int. Cancer49: 254-259 (1991).
J.C. Murray et al., “Flavone Acetic Acid Potentiates the Induction of Endothelial Procoagulant Activity by Tumor Necrosis Factor,”Eur. J. Cancer27: 765-770 (1991).
Y. Sawada et al., “Hemostatic Plug Formation in Normal and von Willebrand Pigs: The Effect of the Administration of Cryoprecipitate and a Monoclonal Antibody to Willebrand Factor,”Blood67: 1229-1239 (1986).
E. Ruoslahti & D. Pierschbacher, “New Perspectives in Cell Adhesion: RGD and Integrins,”Science238: 491-497 (1987).
L.De Marco et al., “Localization and Characterization of an &agr;-Thrombin-binding Site on Platelet Glycoprotein Ib&agr;,”J. Biol. Chem.283: 6478-6484 (1994).
H.R. Gralnick et al., “High-affinity &agr;-Thrombin Binding to Platelet Glycoprotein Ib&agr;: Identification of Two Binding Domains,”Proc. Natl. Acad. Sci. USA91:6334-6338 (1994).
H.R. Gralnick et al., “The Presence and Function of the Seven Transmembrane Thrombin Receptor on Bernard-Soulier Platelets,”Blood80:265a (1992).
J.Y.T. Lam et al., “Is Vasospasm Related to Platelet Deposition? Relationship in a Porcine Preparation of Arterial Injury in Vivo,”Circulation75: 243-248 (1987).
L.L. Thomsen et al., “Evidence for the Production of Nitric Oxide by Activated Macrophages Treated with Antitumo Agents Flavone-8-acetic acid and Xanthenone-4-acetic acid,”Cancer Res.50: 966-6970 (1990).
M.E. Watts et al., “Flavone Acetic Acid as a Modifier of Endothelial Cell Function,”Int. J. Radiat. Oncol. Biol. Phys22: 431-435 (1992).
D. Tousoulis et al., “Inhibition of Cyclic Flow Variations by von Willebrand Factor—Glycoprotein Ib Binding Domain,”Circulation93: 1255 (1996).
I.A. McGhie et al., “Abolition of Cyclic Flow Variations in Stenosed, Endothelium-Induced Coronary Arteries in Nonhuman Primates with a Peptide Fragment (VCL) Derived from Human Plasma von Willebrand Factor
Barts Samuel
Christie Parker & Hale LLP
Khare Devesh
LandOfFree
Use of flavone 8-acetic acid in vascular and cardiovascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of flavone 8-acetic acid in vascular and cardiovascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of flavone 8-acetic acid in vascular and cardiovascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3043671